EBS Q3 2021 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$433M

Q3 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$329M-14.6% YoY

Gross Profit

$63M19.1% margin

Operating Income

-$35M-10.5% margin

Net Income

-$33M-9.9% margin

EPS (Diluted)

$-0.61

QoQ Revenue Growth

-17.2%

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

-$39M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$2.9B

Total Liabilities

$1.3B

Stockholders' Equity

$1.5B

Cash & Equivalents

$404M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$329M	$385M	-14.6%
Gross Profit	$63M	$181M	-65.3%
Operating Income	-$35M	$61M	-156.6%
Net Income	-$33M	$40M	-182.8%

Revenue Segments

Product

$271M82%

Contract Development And Manufacturing

$42M13%

Contracts and Grants

$17M5%

Geographic Segments

Non-US

$269M67%

UNITED STATES

$130M33%